# Viemed Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Viemed Healthcare, Inc.](/companies/vmd.md) (CIK 1729149)
- Form: 10-Q
- Filed: 2021-11-02
- Accepted by EDGAR: Nov 1, 2021, 17:44 ET
- Period: 2021-09-30
- Accession: 0001729149-21-000137
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1729149/000172914921000137/vmd-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1729149/000172914921000137/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $29.3m | us-gaap:Revenues |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $85.1m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $10.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $31.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | $18.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-09-30 | $53.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $576.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-07-01 to 2021-09-30 | $13.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-01-01 to 2021-09-30 | $40.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | $2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | $6.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | $1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | $5.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 40,659,353 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 40,716,747 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | $13.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $13.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2021-01-01 to 2021-09-30 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-09-30 | $26.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $47.4m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $115.5m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $20.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $26.1m | us-gaap:Liabilities |
| Long-term debt | at 2021-09-30 | $4.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-09-30 | $1.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-09-30 | $89.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1729149/000172914921000137/vmd-20210930.htm

Filed Nov 2, 2021.
Source: SEC EDGAR, the filing index for accession 0001729149-21-000137. Last ingested by Listed: Nov 4, 2026, 19:03 ET. No prices; not investment advice.
